Physician profile
Daina Ringus
NPI 1205383874
$1,712.27
in general payments reported to CMS, 2019-2025
10 companies · $658 in 2025
The $658 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $510 · 2024: $544 · 2025: $658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,712.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $534.07 | 2023-2025 | Tezspire, Airsupra, Fasenra |
| Genzyme Corporation | $272.10 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $268.75 | 2023-2025 | Dupixent |
| Blueprint Medicines Corporation | $249.37 | 2023-2025 | Ayvakit |
| Amgen INC. | $114.07 | 2023 | Tezspire |
| Novartis Pharmaceuticals Corporation | $105.08 | 2024-2025 | |
| Ars Pharmaceuticals Operations, INC. | $50.12 | 2025 | Neffy |
| Lilly USA, LLC | $42.91 | 2025 | Taltz |
| Glaxosmithkline, LLC. | $39.68 | 2025 | Nucala |
| Incyte Corporation | $36.12 | 2025 | Opzelura |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daina Ringus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.